Company intelligence / Profile preview

Valcare Medical

Herzliya, Tel Aviv District, Israelvalcaremedical.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Valcare Medical’s AMEND™ Trans-Septal System has demonstrated positive clinical efficacy out to 6 months in a first-in-human study of 17 patients. The company is enrolling patients in an EU pilot study and has received FDA approval to initiate an Early Feasibility Study in the US. The product is investigational only and not yet commercially available[5][6][8].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

AMEND Trans-Septal System

Phase 1

Indications: Mitral regurgitation

Beyond the preview

Go deeper on Valcare Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valcare Medical.

Explore the full profile